ASCO 2023 | Risk of infection and mitigation strategies in patients with myeloma treated with bispecifics
The use of bispecific antibodies in the treatment of relapsed/refractory (R/R) multiple myeloma is showing early promising overall response rates (ORR) in heavily pretreated patients. However, there is a concern over the risk of infectious complications associated with the use of bispecifics. In this interview, Hans Lee, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the risk of infection and mitigation strategies in patients with multiple myeloma treated with bispecific antibodies, including the importance of infection screening and surveillance from the onset of treatment, and the use of prophylaxis, vaccination, and IVIg support during treatment. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
